Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs MRVL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRVL's multiple
Needs MRVL P/E.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
MARVELL TECHNOLOGY, INC · implied price per share
Bear
$17.97
Base
$21.61
Bull
$26.34
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
HUM vs UNH
Elevance Health, Inc.
HUM vs ELV
CVS HEALTH Corp
HUM vs CVS
Cigna Group
HUM vs CI
CENTENE CORP
HUM vs CNC
Oscar Health, Inc.
HUM vs OSCR
INTEL CORP
HUM vs INTC
NVIDIA CORP
HUM vs NVDA
ADVANCED MICRO DEVICES INC
HUM vs AMD
Broadcom Inc.
HUM vs AVGO
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HUM's current margin profile and balance-sheet strength can persist while the market continues to value it below MRVL-implied P/E framework, then HUM looks attractive to own because the model implies 65.8% upside from $374.50 to $621.09.
HUM trades at $374.50 versus a P/E-implied price of $621.09, suggesting 65.8% upside on this framework. The stock is also inside its historical band of $337.05 to $411.95, indicating the current price is near the upper end of its own recent range even though it remains below MRVL-implied valuation.
Supporting Metrics
